Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor
Aandeel

Genfit FR0004163111

Laatste koers (eur)

3,575

  • Verschil

    -0,105 -2,85%

  • Volume

    366.661 Gem. (3M) 214,7K

  • Bied

    -  

  • Laat

    -  
+ In watchlist

Genfit - 2023

72 Posts
Pagina: «« 1 2 3 4 | Laatste | Omlaag ↓
  1. Kanhetlager 11 november 2024 15:53

    • Kanhetlager

      Lid sinds: 11 jul 2024

      Laatste bezoek: 31 jan 2025

    • Aanbevelingen

      Ontvangen: 221

      Gegeven: 228

    •    Aantal posts: 617

    quote:

    Pjotr schreef op 8 november 2024 18:07:

    Geen beste dag voor Genfit. Bijna 10% eraf
    Geen herstel vandaag. Toch net wat gekocht.
  6. Pjotr 4 december 2024 09:22

    • Pjotr

      Lid sinds: 04 jan 2018

      Laatste bezoek: 31 jan 2025

    • Aanbevelingen

      Ontvangen: 171

      Gegeven: 100

    •    Aantal posts: 507

    een maand geleden werd er flink gekocht boven de 5 euro. Zoveel is er toch niet veranderd.
  8. Kanhetlager 6 december 2024 11:35

    • Kanhetlager

      Lid sinds: 11 jul 2024

      Laatste bezoek: 31 jan 2025

    • Aanbevelingen

      Ontvangen: 221

      Gegeven: 228

    •    Aantal posts: 617

    quote:

    Pjotr schreef op 4 december 2024 09:22:

    een maand geleden werd er flink gekocht boven de 5 euro. Zoveel is er toch niet veranderd.
    Was dat niet vanwege overnamespeculatie?
  13. forum rang 10 DeZwarteRidder 30 januari 2025 13:56

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 31 jan 2025

    • Aanbevelingen

      Ontvangen: 23977

      Gegeven: 10500

    •    Aantal posts: 101.856

    GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

    January 30, 2025 02:40 ET | Source: GENFIT S.A.

    Share

    GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital:
    €130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones
    Closing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meeting
    Financing would extend cash runway beyond the end of 2027, assuming drawdown of all instalments
    Proceeds to further strengthen the development of the ACLF pipeline
    In return, HCRx will receive a portion of royalties on global1 sales of Iqirvo® (elafibranor) payable to GENFIT under its licensing agreement with Ipsen, up to an agreed upon cap after which all future royalties will revert back to GENFIT
    GENFIT retains rights to all future regulatory, commercial and sales-based milestone payments from Ipsen under the Ipsen agreement
    GENFIT to concurrently propose a repurchase of the 2025 OCEANEs aiming to completely eliminate GENFIT’s convertible debt overhang

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 30, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces that it has entered into a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to €185 million, and debt overhang resolution plan.

    Pascal Prigent, CEO of GENFIT, commented: “This non-dilutive financial agreement is a pivotal step in strengthening our financial outlook, extending our cash runway beyond 2027. We are also proposing to repurchase the outstanding 2025 OCEANE bonds to eliminate our convertible debt overhang. This financing transaction will position GENFIT to operate on strong foundations to deliver on its R&D pipeline objectives in ACLF.”

    Clarke Futch, Chairman and Chief Executive Officer of HCRx, added: “With this investment, HCRx underscores its commitment to supporting innovative biopharmaceutical companies that create long-term value. We firmly believe in the strong potential that Iqirvo® delivers to patients with high unmet medical need, and are excited to collaborate with GENFIT on this transaction.”

    Highlights

    Corporate context

    In December 2021, GENFIT entered into a long-term strategic partnership with Ipsen (the “Ipsen agreement”). The agreement grants Ipsen an exclusive worldwide license (excluding China, Hong Kong, Taiwan and Macau for which Terns Pharmaceuticals has a prior license) to develop, manufacture, and commercialize elafibranor for people living with Primary Biliary Cholangitis (PBC), and in other indications. Under the terms of the Ipsen agreement, GENFIT is eligible for regulatory, commercial, and sales-based milestone payments and royalties, based on product sales.

    In 2024, Iqirvo® (elafibranor) received accelerated approval from the U.S. Federal Drug Administration for sale in the United States and conditional
72 Posts
Pagina: «« 1 2 3 4 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in
Genfit

Van de redactie

  1. 7 farmaceutische dividendtoppers
  2. Markt verwacht nieuwe rentepauze Fed en dit zijn de opvallendste uitspraken van Powell
  3. Deze 5 aandelen zijn favoriet bij analisten op Wall Street
  4. Stem op uw favoriete AEX-aandeel voor februari
  5. TA-column Nico Bakker: ASML scoort prima
  6. 5 cyclische aandelen met veel potentieel
Meer artikelen